Russian drugmakers bypass Gilead to unveil COVID-19 generic
04-02-2021
eyesonmilan / Shutterstock.com
The US government doesn't co-own patents covering Gilead Science’s drug remdesivir, according to a report by the Government Accountability Office (GAO).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
COVID-19, remdesIivir, patent rights, GAO, US federal government, Centers for Disease Control and Prevention, the Department of Defense
